This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Tackle Market Uncertainty With These 3 Quality Dividend ETFs
by Zacks Equity Research
Consider these three dividend ETFs for your portfolio to fight growing market uncertainty.
Is a Recession in the Cards? 4 Safe Bets for Your Portfolio
by Indrajit Bandyopadhyay
After nearly a decade of the global financial crisis of 2007-2008, some analysts believe that the threat of another recession lurks. However, the time and its impact is yet to be ascertained.
Merck KGaA's Tepotinib Gets Fast Track Designation in Japan
by Zacks Equity Research
Merck KGaA's (MKGAF) lung cancer candidate, tepotinib gets fast track designation in Japan.
Glaxo (GSK) Buys Novartis' Stake in Consumer Healthcare JV
by Zacks Equity Research
Glaxo (GSK) is buying out Novartis' stake in their Consumer Healthcare JV. Glaxo is also initiating a strategic review of its Horlicks business and its majority stake in Indian subsidiary.
4 Top-Ranked Drug/Biotech Stocks to Buy as Q1 Nears End
by Kinjel Shah
The first quarter of 2018 is drawing to a close. With the outlook optimistic for the rest of the year, we highlight four drug/biotech stocks worth buying
Pfizer's Chantix Fails in Phase IV Study in Young Smokers
by Zacks Equity Research
Pfizer's (PFE) Chantix fails to meet primary endpoint in a phase IV study, a regulatory post-marketing commitment.
Glaxo Drops Bid for Pfizer Unit, Shingrix Gains EU/Japan Nod
by Zacks Equity Research
Glaxo (GSK) withdraws from the process related to Pfizer's Consumer Health unit. Shingrix gains regulatory approval in Japan and EU.
Wall Street Braces for Ugliest March: 5 Ultra-Safe Picks
by Tirthankar Chakraborty
The Dow is on track for its worst March in nearly 40 years, while the month is likely to be most awful for the S&P 500 and the Nasdaq since 2001.
Novartis Gets Positive CHMP Opinion on Biosimilar Remicade
by Zacks Equity Research
The CHMP gave a positive opinion to Novartis (NVS) proposed biosimilar of Remicade for all of the branded drug's indications. A decision from the EMA is expected shortly.
The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer
Cancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in Focus
by Zacks Equity Research
Novartis' (NVS) Tasigna and Seattle Genetics' (SGEN) Adcetris receive regulatory approvals for label expansion. Pfizer's label expansion application for Xtandi gets priority review.
Merck Gets European Committee Vote for Veterinary Product
by Zacks Equity Research
Merck (MRK) is seeking approval of Bravecto Plus, a spot-on solution for cats. The drug is part of the company's Animal Health unit.
4 Reasons Why Glaxo (GSK) Stock Can be a Great Pick in '18
by Zacks Equity Research
Glaxo (GSK) has a Zacks Rank #2 (Buy). Its shares have outperformed the industry this year so far. Earnings estimates are also on the rise.
Pfizer's Xtandi Label Expansion Filing Gets Priority Review
by Zacks Equity Research
FDA grants priority review status to Pfizer's(PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.
J&J Gets $2.1B Offer for LifeScan Diabetes Device Unit
by Zacks Equity Research
J&J (JNJ) receives an offer for its LifeScan unit from private firm, Platinum Equity. It has time until Jun 15 to accept the offer, failing which it will expire.
Should Value Investors Pick Pfizer (PFE) Stock Now?
by Zacks Equity Research
Let's see if Pfizer Inc. (PFE) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Dow 30 Stock Roundup: Boeing JV Wins $354M Satellite Contract, Merck's Keytruda Gets Priority Review
by Swarup Gupta
The Dow traversed a difficult week, declining over three consecutive trading sessions.
J&J's (JNJ) Erdafitinib Gets Breakthrough Therapy Status
by Zacks Equity Research
The breakthrough therapy designation for J&J's (JNJ) erdafitinib was based on efficacy findings from a phase II study, evaluating it in advanced urothelial cancer.
Pfizer (PFE) and Delta Air Lines (DAL): Growth & Income Stocks
by Brian Hamilton
This week I discuss two dividend paying companies that both beat top and bottom line expectations and are expected to greatly benefit from the new tax reform law over the next few years. These companies are Pfizer Inc. (PFE), and Delta Air lines Inc. (DAL).
Biotech Stock Roundup: REGN Cuts Praluent Price, OREX to File for Bankruptcy
by Zacks Equity Research
The biotech sector was in focus last week with key news - Orexigen going bankrupt, Biogen acquires asset from Pfizer, Regeneron cuts Praluent price among others.
Biogen to Buy Mid-Stage Neuropsychiatry Asset From Pfizer
by Zacks Equity Research
Biogen (BIIB) agrees to pay $75 million upfront to buy mid-stage candidate from Pfizer, which is being developed for cognitive impairment associated with schizophrenia (CIAS).
Pfizer Gets FDA Panel Backing for New Indication for Xeljanz
by Zacks Equity Research
Pfizer's (PFE) Xeljanz received a unanimous vote from an FDA advisory committee to include the ulcerative colitis (UC) indication in its label .
Pharma Stock Roundup: MRK Signs New Cancer Deal, DERM's Acne Candidate Fails
by Zacks Equity Research
Key announcements include the failure of Dermira's (DERM) acne candidate in two pivotal late-stage studies and Merck's oncology collaboration with Japan's Eisai.
Is Big Pharma Using Corporate Tax Savings to Lower Drug Costs?
by Zacks Equity Research
Big pharma companies are using their savings in tax to boost shareholders' wealth through dividends or share buybacks, ignoring consumers.
How to Invest in ETFs Backed by Women Power
by Sweta Killa
Given the long history of outperformance, many investors are seeking to add female-centric companies to their portfolio although the list is still small.